NeuroPace (NASDAQ:NPCE) is a medical device company that develops and markets solutions for treating neurological disorders. Its main product is the RNS System, a brain-responsive neurostimulation system designed to prevent seizures in individuals with drug-resistant epilepsy. On May 15, 2026, analyst firm H.C. Wainwright maintained its Buy rating for NeuroPace and raised its price target to $20.00.
The analyst's confidence reflects the company's strong first-quarter 2026 performance. As highlighted by Zacks, NeuroPace reported an adjusted loss of $0.13 per share. This result is a significant improvement from the $0.18 loss in the prior-year period and is narrower than the consensus estimate of a $0.19 loss per share.
Revenue for the quarter reached $22.1 million, beating analyst expectations. This was primarily driven by the strong performance of its RNS System, which generated $21.7 million in sales. This represents a 19.5% increase in sales for the system compared to the same quarter in the previous year, showing strong product demand.
Following these results, NeuroPace raised its revenue guidance for the full year of 2026. The company now anticipates its RNS System sales will grow between 21% and 23% for the year. This updated forecast signals management's confidence in its continued performance and market expansion.
The company also shows progress in its operational efficiency. Its adjusted EBITDA loss improved, narrowing to $3.3 million from a $4.1 million loss in the first quarter of 2025. Adjusted EBITDA is a measure of operating performance that excludes non-cash expenses like depreciation, providing a clearer view of a company's core profitability.
